Stomach cancer Archives

July 3, 2024

Amended Trial: Nataliya Uboha Gives an Update on the EA2183 Trial for Patients with Esophageal and Gastric Adenocarcinoma

The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread

May 1, 2024

May 1, 2024

NCCN Recommends Universal Testing for Microsatellite Instability by PCR/NGS or Mismatch Repair by IHC for All Newly Diagnosed Gastric Cancer Patients

EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer

October 19, 2023

Now Enrolling: EA2212 for Patients with Gastric and/or Gastroesophageal Junction Cancer

This randomized phase 2 study is assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer